Results 71 to 80 of about 1,109,482 (395)

An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

Hepatology, 2011
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV).
M. Ghany, D. Nelson, D. Strader, David L. Thomas, L. Seeff   +4 more
semanticscholar   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

Advanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras, Imelda Raczkiewicz, Peggy Bouquet, Jean‐Philippe Dacquin, Jeremy Dhainaut, Anne Goffard, Christophe Volkringer   +6 more
wiley   +1 more source

Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran [PDF]

, 2014
Background: Hepatitis B infection, caused by hepatitis B Virus (HBV), is one of the major global public health problems. Hepatitis B Virus genotypes appear to show varying geographic distribution with possible pathogenic and therapeutic differences ...
Bahramali G, Hannoun C, Kao JH, Karimi A, Karimi A, Karimi A, Kidd-Ljunggren K, Lindh M, Maddrey WC, Mahoney FJ, Merat S, Mojiri A, Okamoto H, Patel PC, Severini A, Wang JH, Yan MH, Zhang XH   +17 more
core   +1 more source

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

Advanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement, Jana Ismail, Josefine Schroeder, Amod Godbole, Johanna Schreiber, Christine Weber, Zoltan Cseresnyes, Marc T. Figge, Bettina Löffler, Ulrich S. Schubert, Stephanie Schubert, Christina Ehrhardt, Carsten Hoffmann   +12 more
wiley   +1 more source

Dynamics of cell population structure in liver biopsy of the patients with chronic hepatitis viral infection [PDF]

, 2012
The cell population analysis of liver biopsies from the patients with both chronic hepatitis, chronic viral hepatitis C (HCV) and chronic viral hepatitis B (HBV) included the comparative evaluation of the specific part of non-parenchymal elements ...
Filimonova, Galina, Hussar, Piret, Tokin, Ivan B., Tokin, Ivan I.   +3 more
core   +3 more sources

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Gastroenterology, 2002
BACKGROUND & AIMS Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established.
T. Poynard, J. Mchutchison, M. Manns, C. Trépo, K. Lindsay, Z. Goodman, M. Ling, J. Albrecht   +7 more
semanticscholar   +1 more source

Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation

Advanced Healthcare Materials, EarlyView.
This review examines how emerging enabling technologies enhance the physiological relevance, scalability, and reproducibility of kidney organoids, while advanced analytical approaches support model validation and deepen mechanistic insight into nephrotoxicity.
Helen Kearney, Silvia M. Mihăilă, Lorenzo Moroni, Carlos Mota   +3 more
wiley   +1 more source

Transcription Factor MafB Suppresses Type I Interferon Production by CD14+ Monocytes in Patients With Chronic Hepatitis C

Frontiers in Microbiology, 2019
Transcription factor MafB regulates differentiation and activity of monocytes/macrophage and is associated with the development of atherosclerosis and cancers.
Tie-Mei Liu, Han Wang, Dong-Na Zhang, Guang-Ze Zhu   +3 more
doaj   +1 more source

Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection

Медицинский совет, 2020
Extrahepatic manifestations occur in more than half of patients with chronic hepatitis C virus infection and may be no less dangerous to the health and life of the patient than the isolated pathology of the liver.
V. V. Tsvetkov, I. I. Tokin, S. A. Pozdnjakova   +2 more
doaj   +1 more source

Vitamin D as One of Predicators of the Stable Viral Response to Antiviral Therapy in Patients with Chronis Hepatitis С [PDF]

, 2016
Chronic hepatitis C (CHC) it is not exceptionally medical problem but a significant social and economic threat, taking into account the unfavorable consequences of this disease: cirrhosis and hepatocellular carcinoma.
Androsova, O. (Olga), Davydyuk, I. (Irina), Moroz, L. (Larisa), Musaev, E. E. (Eltun)   +3 more
core